Analysis of the tumorigenicity of the X gene of hepatitis B virus in a nontransformed hepatocyte cell line and the effects of cotransfection with a murine p53 mutant equivalent to human codon 249

Hepatology

Volumn 24, Issue 5, 1996, Pages 1024-1033

  Oguey, Delphine ^a,c   Dumenco, Luba L ^a   Pierce, Robert H ^b   Fausto, Nelson ^b,d  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Ctr Pluridisciplinaire d'Oncologie   (Switzerland)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53; VIRUS DNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CODON; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE MUTATION; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOCYTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; MUTANT; NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; VIRUS GENE;

EID: 0029957571     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008903370     Document Type: Article

References (54)

1. Johnson PJ. Hepatitis B virus and primary liver cancer. In: Bréchot C, ed. Primary liver cancer: etiological and progression factors. Paris: CRC, 1994:31-39.
2. Kew MC. Tumours of the liver. Scand J Gastroenterol 1992;192(suppl)39-42.
3. Chisari F, Ferrari C, Mondelli M. Hepatitis B virus structure and biology. Microbial Pathogenesis 1989;6:311-325.
4. Nagaya T, Nakamura T, Tokino T, Tsurimoto T, Imai M, Mayumi T, Kamino K. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1987;1:773-782.
5. Slagle B, Lee T, Butel J. Hepatitis B virus and hepatocellular carcinoma. Prog Med Virol 1992;39:167-203.
6. Chen H, Kaneko S, Girones R, Anderson R, Hornbuckle WE, Tennant BC, Cote PJ, et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 1993;67:1218-1226.
7. Rossner M. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 1992;36:101-117.
8. Balsano C, Avantaggiati ML, Natoli G, De ME, Will H, Perricaudet M, Levrero M. Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the c-myc protooncogene at the transcriptional level. Biochem Biophys Res Commun 1991;176:985-992.
9. Twu JS, Chu K, Robinson WS. Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. Proc Natl Acad Sci USA 1989;86:5168-5172.
10. Seto E, Mitchell PJ, Yen TS. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 1990; 344:72-74.
11. Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991;252:842-844.
12. Lucito R, Schneider RJ. Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J Virol 1992;66:983-991.
13. Kim C-M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-320.
14. Koike K, Moriya K, Yotsuyanagi H, Endo Y, Miyamura T, Kurokawa K. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. HEPATOLOGY 1994;19:810-819.
15. Balsano C, Billet O, Bennoun M, Cavard C, Zider A, Grimber G, Natoli G, et al. Hepatitis B virus X gene product acts as a transactivator in vivo. J Hepatol 1994;21:103-109.
16. Lee T-H, Finegold M, Shen R-F, DeMayo J, Woo S, Butel J. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990;64:5939-5947.
17. Höhne M, Schaefer S, Seifer M, Feitelson MA, Paul D, Gerlich WH. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J 1990;9:1137-1145.
18. Seifer M, Hohne M, Schaefer S, Gerlich WH. In vitro tumorigenicity of hepatitis B virus DNA and HBx protein. J Hepatol 1991;13:S61-S65.
19. Koike K, Moriya K, Yotsuyanagi H, Lino S, Kurokawa K. Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts. J Clin Invest 1994;94:44-49.
20. Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci USA 199;92:11215-11219.
21. Wu JC, Merlino G, Fausto N. Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor α. Proc Natl Acad Sci USA 1994; 91:674-678.
22. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427-428.
23. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350: 429-431.
24. Coursaget P, Depril N, Chabaud M, Nandi R, Mayelo V, LeCann P, Yvonnet B. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer 1993;67:1395-1397.
25. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu J-R, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994;91:2230-2234.
26. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-1117.
27. Dumenco LL, Oguey D, Wu JC, Messier N, Fausto N. Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. HEPATOLOGY 1995;22:1279-1288.
28. Fujiyama A, Miyanohara A, Nozaki C, Yoneyama T, Ohtomo N, Matsubara K. Cloning and structural analysis of hepatitis B virus DNAs, subtype adr. Nucleic Acids Res 1983;11:4601-4610.
29. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-680.
30. Lo SJ, Chien ML, Lee YH. Characteristics of the X gene of hepatitis B virus. Virology 1988;167:289-292.
31. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor, 1989.
32. Macpherson I, Montagnier L. Agar suspension cultures for the selective assay of cells transformed by polyoma virus. Virology 1964;23:291-294.
33. Braun L, Mikumo R, Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res 1989;49:1554-1561.
34. Snedecor G, Cochran W. Statistical methods. Ames, IA: Iowa State University, 1967.
35. Rabinovitch PS. DNA content histogram and cell cycle analysis. Methods Cell Biol 1994;41:263-296.
36. Wu HL, Chen PJ, Lin MH, Chen DS. Temporal aspects of major viral transcript expression in Hep G2 cells transfected with cloned hepatitis B virus DNA: with emphasis on the X transcript. Virology 1991;185:644-651.
37. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-47.
38. Runkel L, Fisher L, Schaller H. Two-codon insertions mutations of the HBx define two separate regions necessary for its transactivation function. Virology 1993;197:529-536.
39. Schek N, Bartenschlager R, Kuhn C, Schaller H. Phosphorylation and rapid turnover of hepatitis B virus X-protein expressed in HepG2 cells from a recombinant vaccinia virus. Oncogene 1991;6:1735-1744.
40. Shirakata Y, Kawada M, Fujiki Y, Sano H, Oda M, Yaginuma K, Kobayashi M, et al. The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn J Cancer Res 1989;80:617-621.
41. Seto E, Yen T. Mutual functional antagonism of the simian virus 40 T antigen and the hepatitis B virus transactivator. J Virol 1991;65:2351-2356.
42. Takada S, Tsuchida N, Kobayashi M, Koike K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J Cancer Res Clin Oncol 1995;121:593-601.
43. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-948.
44. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty T. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-935.
45. Puisieux A, Ji J, Guillot C, Legros Y, Soussi T, Isselbacher K, Ozturk M. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci USA 1995;92:1342-1346.
46. Cross J, Wen P, Rutter W. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci USA 1993;90:8078-8082.
47. Kekulé AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993;361:742-745.
48. Kekulé AS. Hepatitis B virus transactivator proteins: the "trans" hypothesis of liver Carcinogenesis. In: Bréchot C, ed. Primary liver cancer: etiological and progression factors. Paris: CRC, Inc., 1994:191-210.
49. Henkler F, Waseem N, Golding MHC, Alison MR, Koshy R. Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus-related human hepatocellular carcinoma. Cancer Res 1995;55:6084-6091.
50. Hollstein MC, Wild CP, Bleicher F, Chutimataewin S, Harris CC, Srivatanakul P, Montesano R. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 1993;53:51-55.
51. Li D, Cao Y, He L, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993;14:169-173.
52. Unsal H, Yakicier C, Marcais C, Kew M, Volkmann M, Zentgraf H, Isselbacher KJ, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994;91:822-826.
53. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356-1359.
54. Slagle BL, Lee T-H, Medina D, Finegold MJ, Butel JS. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 1996;15:261-269.